KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Beginning Cash Balance: 2016-2024

Historic Beginning Cash Balance for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $91.2 million.

  • Amneal Pharmaceuticals' Beginning Cash Balance rose 2.72% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 54.87%. This contributed to the annual value of $91.2 million for FY2024, which is 229.84% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Beginning Cash Balance of $91.2 million as of FY2024, which was up 229.84% from $27.7 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Beginning Cash Balance registered a high of $338.2 million during FY2021, and its lowest value of $27.7 million during FY2023.
  • In the last 3 years, Amneal Pharmaceuticals' Beginning Cash Balance had a median value of $91.2 million in 2024 and averaged $122.1 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Beginning Cash Balance plummeted by 88.82% in 2023 and then soared by 229.84% in 2024.
  • Amneal Pharmaceuticals' Beginning Cash Balance (Yearly) stood at $147.1 million in 2020, then skyrocketed by 129.93% to $338.2 million in 2021, then decreased by 26.82% to $247.5 million in 2022, then crashed by 88.82% to $27.7 million in 2023, then skyrocketed by 229.84% to $91.2 million in 2024.